Key Highlights

  • Shares are up 19.66% in pre-market trading to $42.18, after closing down 1.15% at $35.25 the prior session.
  • The pivotal Phase 3 CHAPTER-3 trial met its primary endpoint, showing an 83% reduction in hereditary angioedema attack rate and an 87% reduction among HAE Type 1/2 patients versus placebo.
  • All secondary efficacy endpoints also achieved statistical significance, alongside a well-tolerated safety profile.
  • Pharvaris is planning to submit a New Drug Application to the FDA in the first half of 2027.

Pharvaris Surges on Positive Phase 3 Trial Results

Pharvaris (NASDAQ:PHVS) shares are up 19.66% in pre-market trading to $42.18, after the company announced statistically significant, positive topline results from its pivotal Phase 3 CHAPTER-3 trial evaluating deucrictibant extended-release tablets for prevention of hereditary angioedema attacks. The stock had closed down 1.15% at $35.25 the prior session, and today's pre-market move puts shares near the top of their 52-week range of $20.65-$38.13.

Pharvaris is a late-stage biopharmaceutical company headquartered in Zug, Switzerland, focused on developing and commercializing therapies for rare, bradykinin-mediated diseases, particularly hereditary angioedema. Its lead candidate, deucrictibant, is an oral small-molecule bradykinin B2-receptor antagonist being developed in both an immediate-release capsule for on-demand treatment of HAE attacks and an extended-release tablet for prophylactic use, with both formulations advancing through Phase 3 clinical trials. Founded in 2015 and led by CEO Berndt Modig, the company employs around 134 people and trades on the Nasdaq Global Select Market.

CHAPTER-3 Trial Meets Primary and Secondary Endpoints

The drug met its primary endpoint with an 83% reduction in monthly attack rate versus placebo, and an 87% reduction among HAE Type 1/2 patients, with all secondary efficacy endpoints also achieving statistical significance alongside a well-tolerated safety profile. This is a major de-risking catalyst investors had been anticipating, with Pharvaris now planning to submit a New Drug Application to the FDA in the first half of 2027.

The strong efficacy data, which came in well above the roughly 44% reduction seen with the current approved oral prophylactic, positions deucrictibant as a potentially best-in-class, convenient oral therapy in the consolidating HAE treatment market. As a clinical-stage company with no approved products, Pharvaris currently generates no significant product Revenue and remains focused on advancing its bradykinin B2-receptor antagonist pipeline toward regulatory approval.

What This Means for Investors

Today's rally reflects a genuine de-risking event for Pharvaris's lead program, with the magnitude of the attack-rate reduction, and its favorable comparison to the existing approved oral prophylactic, suggesting deucrictibant could capture meaningful share in the hereditary angioedema market if approved. The fact that all secondary endpoints also reached statistical significance reduces the risk that the primary result was an isolated finding, and the well-tolerated safety profile removes a key overhang that has weighed on other bradykinin-pathway therapies in development.

With an NDA submission targeted for the first half of 2027, the stock's next major catalysts will be regulatory in nature, and investors will be watching for FDA feedback on the submission package as the clearest signal of approval timing and probability. As a clinical-stage company that has not yet generated meaningful product revenue, Pharvaris's valuation will likely remain heavily tied to binary regulatory and clinical outcomes over the next 12 to 18 months, making today's positive data an important step in de-risking the path toward commercialization rather than a final confirmation of it.